Characterization of human soft-tissue sarcoma xenografts for use in secondary drug screening
1998

Study of Human Soft-Tissue Sarcoma Xenografts for Drug Testing

Sample size: 10 publication Evidence: moderate

Author Information

Author(s): E Boven, HM Pinedo, AH van Hattum, PG Scheffer, WHM Peters, CAM Erkelens, HMM Schlooper, CM Kuiper, J van Ark-Ottel, G Giaccone

Primary Institution: Academic Hospital Vrije Universiteit, Amsterdam, The Netherlands

Hypothesis

The study aims to characterize human soft-tissue sarcoma xenografts to understand their chemosensitivity to various anti-cancer agents.

Conclusion

The chemosensitivity of the STS xenografts reflects clinical response rates in phase II trials on the same compounds in adult STS patients.

Supporting Evidence

  • Growth inhibition > 75% was measured for doxorubicin in 20% of the STS xenografts.
  • 30% growth inhibition was observed for cyclophosphamide in the xenografts.
  • 20% growth inhibition was noted for vincristine in the xenografts.
  • Etoposide was not effective in the STS xenografts.
  • Three out of ten STS xenografts showed detectable MDR1 mRNA.

Takeaway

Researchers grew tumors from patients in mice to see how well different cancer drugs worked, finding that some drugs worked better than others.

Methodology

Ten human soft-tissue sarcoma xenografts were established in nude mice and tested for sensitivity to five anti-cancer agents.

Limitations

The study does not account for all potential drug resistance mechanisms in soft-tissue sarcomas.

Participant Demographics

Nine xenografts originated from patients needing chemotherapy.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication